查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1701336

循环性肿瘤细胞（CTC）市场规模、份额、趋势分析报告：按应用、检体、产品、技术、最终用途、地区、细分市场预测，2025-2030 年

Circulating Tumor Cells Market Size, Share & Trends Analysis Report By Application (Clinical, Research), By Specimen (Bone Marrow, Blood), By Product, By Technology, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

循环性肿瘤细胞（CTC）市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球循环性肿瘤细胞（CTC）市场规模预计到2030年将达到249.6亿美元，2025年至2030年期间的复合年增长率为12.2%。

这是由全球癌症盛行率上升、对非侵入性癌症诊断工具的需求增加以及循环性肿瘤细胞(CTC) 技术的进步所推动的。

近年来，CTC 越来越多地用于确定癌症预后并帮助临床医生决定需要何种类型的治疗方法来治疗癌症。 CTC在癌症管理的各个领域有着广泛的应用，包括早期检测、癌症復发风险评估、治疗指南以及癌症治疗期间患者的持续监测。预计在预测期内，使用 CTC 进行癌症诊断和监测的各种肿瘤标记的开发将推动 CTC 的采用。因此，可以得出结论，检测癌症患者周边血液中的 CTC 是一种很有前途的诊断工具。例如，CTC 量化和基因组分析可以实现对前列腺癌的经济有效且准确的非侵入性监测。 CTC 的检测可以预测癌症患者的存活率。

这些细胞在罕见癌症中的适用性有限，在一定程度上阻碍了收益成长。循环性肿瘤细胞（CTC）不适用于以 EpCAM 阴性或低表达为特征的肿瘤，例如神经源性癌。例如，几乎没有证据可以描述肉瘤的循环性肿瘤细胞（CTC）。相反，许多分离这些细胞的方法正在被研究，包括使用针对上皮抗原的抗体的方法，希望这些挑战能在不久的将来克服。

然而，近年来，为了加速价值链的形成和CTC市场的成长，各大公司进行了一系列收购，并透过与製药公司的大量合作实现了技术的集中化，促进了实用化。例如，2023 年 6 月，华盛顿大学医学院与西雅图的生物技术公司 RareCyte 合作开发了一项新测试，用于检测转移性癌症排放到血液中的癌细胞。此外，研究表明，了解血液中的循环性肿瘤细胞（CTC）有助于追踪癌细胞的变化，从而优化治疗。

循环性肿瘤细胞（CTC）市场报告重点

  • 从技术角度来看，由于 CTC 富集和分离产品的供应不断增加、利用率高以及全球产品渗透率不断提高，预计 CTC 检测和富集方法部门将在 2024 年占据最大的收入份额，达到 40.92%。
  • 由于 CTC 分析在临床实验研究、药物开发和生物标记研究中的应用日益增多，预计其在预测期内的复合年增长率将最快。
  • 根据应用，研究领域预计将在 2024 年占据市场主导地位，并在 2025 年至 2030 年期间实现最快的复合年增长率。
  • 根据产品，套件和试剂预计将在 2024 年占据市场主导地位，并预计在 2025 年至 2030 年的预测期内以最快的速度成长。
  • 根据检体，血液部分在 2024 年占据了市场主导地位。预计其他体液部分将在 2025 年至 2030 年期间以最快的复合年增长率增长。
  • 根据最终用途，由于越来越关注癌症诊断和治疗的研究和开发活动，研究和学术机构部门在 2024 年占据了市场主导地位。
  • 由于主要市场参与者 Bio-Techne Corporation、Precision Medicine Group LLC、Epic Sc​​iences、APPLIED DNA SCIENCES, INC. 和 LungLife AI, Inc. 的存在，以及该地区製药和生物技术研究领域的成长等因素，预计北美将在 2024 年主导 CTC 市场。
  • 由于多家公司扩大在日本等国家的业务，预计亚太地区在预测期内的复合年增长率将最快。

目录

第一章调查方法与范围

第二章执行摘要

第三章循环性肿瘤细胞（CTC）市场变数、趋势与范围

  • 市场展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 循环性肿瘤细胞（CTC）市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • COVID-19影响分析

第四章循环性肿瘤细胞（CTC）市场：按技术分類的估值和趋势分析

  • 技术细分仪表板
  • 全球循环性肿瘤细胞（CTC）市场技术变革分析
  • 全球循环性肿瘤细胞(CTC) 市场规模及技术趋势分析（2018-2030 年）
  • 2018年至2030年市场规模、预测及趋势分析
    • CTC检测和富集方法
    • 直接CTC检测方法
    • CTC分析

第五章循环性肿瘤细胞（CTC）市场：按应用的估计和趋势分析

  • 应用程式细分仪表板
  • 全球循环性肿瘤细胞（CTC）市场应用趋势分析
  • 全球循环性肿瘤细胞（CTC）市场规模及应用趋势分析（2018-2030）
  • 2018年至2030年市场规模、预测及趋势分析
    • 临床
    • 调查

第六章循环性肿瘤细胞（CTC）市场：按产品进行的估计和趋势分析

  • 产品细分仪表板
  • 全球循环性肿瘤细胞（CTC）市场产品差异分析
  • 全球循环性肿瘤细胞（CTC）市场规模及趋势分析（依产品，2018-2030）
  • 2018年至2030年市场规模、预测及趋势分析
    • 套件和试剂
    • 采血管
    • 设备或系统

第七章循环性肿瘤细胞（CTC）市场：样本检体与趋势分析

  • 检体细分仪表板
  • 全球循环性肿瘤细胞（CTC）市场检体变异性分析
  • 全球循环性肿瘤细胞（CTC）市场规模及趋势分析（依检体，2018-2030）
  • 2018年至2030年市场规模、预测及趋势分析
    • 血
    • 骨髓
    • 其他体液

第 8 章循环性肿瘤细胞(CTC) 市场：按最终用途进行的估计和趋势分析

  • 最终用途细分仪表板
  • 全球循环性肿瘤细胞（CTC）市场最终用途变化分析
  • 2018-2030年全球循环性肿瘤细胞（CTC）市场规模及趋势分析（依最终用途）
  • 2018年至2030年市场规模、预测及趋势分析
    • 研究和学术机构
    • 医院和诊所
    • 诊断中心

第九章循环性肿瘤细胞（CTC）市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第十章 竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • 主要客户
    • 主要企业地位分析（2024年）
    • QIAGEN
    • Bio-Techne Corp.
    • Precision Medicine Group, LLC.
    • Bio-Rad Laboratories, Inc.
    • Natera, Inc.
    • Illumina, Inc.
    • Cell Microsystems
    • Greiner Bio One International GmbH
    • Ikonisys Inc.
    • Miltenyi Biotec
    • Creative Bioarray
    • BioFluidica
    • Abnova Corporation
    • Biolidics Limited
    • Creativ MicroTech, Inc.
    • LungLife AI
    • Epic Sciences
    • Rarecells Diagnostics
    • ScreenCell
    • Menarini Silicon Biosystems
    • APPLIED DNA SCIENCES, INC.
    • Sysmex Corporation
    • STEMCELL Technologies, Inc.
Product Code: 978-1-68038-287-7

Circulating Tumor Cells Market Growth & Trends:

The global circulating tumor cells market size is estimated to reach USD 24.96 billion by 2030, expanding at a CAGR of 12.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. This is attributed to rising prevalence of cancer worldwide, increasing demand for non-invasive cancer diagnostic tools, and advancements in circulating tumor cells (CTC) technologies.

In recent years, CTCs are increasingly used for determining the prognosis of cancer and helping clinicians decide the type of therapy required for cancer treatment. CTCs have wide applications in several areas of cancer management-early detection of cancer, risk assessment of cancer recurrence, guidance for therapies, and continuous monitoring of a patient during cancer treatment. The development of various tumor markers utilizing CTCs, which can be used to diagnose or monitor cancer, is expected to boost the adoption of CTCs over the forecast period. Therefore, it can be concluded that the detection of CTCs in the peripheral blood of patients with cancer acts as a promising diagnostic tool. For instance, quantitation and genomic profiling of CTCs enables cost-effective & accurate noninvasive monitoring of prostate cancer. The detection of CTCs is predictive for survival of cancer patients.

The limited applicability of these cells in rare cancers has hampered revenue growth to a certain extent. Circulating tumor cells are not applicable to tumors characterized by EpCAM negativity or low expression, such as neurogenic cancers. For instance, there is negligible evidence for the characterization of circulating tumor cells for sarcoma. Conversely, numerous methods are being studied for the isolation of these cells, which include methods based on epithelial antigen-targeted antibodies, anticipating to overcome these challenges in the near future.

However, in recent years, there has been a push for practical application, largely as a result of a wave of large players centralizing the technology through acquisitions and numerous partnerships with pharmaceutical firms to advance the formation of a value chain and speed up the CTC market's growth. For instance, in June 2023, to develop a novel test for the detection of tumor cells that metastatic cancers shed into the blood, the University of Washington School of Medicine collaborated with RareCyte, Inc., which is a biotech company headquartered in Seattle. In addition, according to the research, the understanding of the circulating tumor cells in the bloodstream can track the changes in tumor cells, thus optimizing the treatment.

Circulating Tumor Cells Market Report Highlights:

  • Based on technology, The CTC detection and enrichment methods segment accounted for the largest revenue share of 40.92% in 2024 owing to the increased availability of products for CTC enrichment and isolation as well as high usage and product penetration across the globe
  • CTC analysis is expected to register the fastest CAGR during the forecast period due to the growing application potential of CTC analysis for investigational research, drug development, and biomarker studies
  • Based on application, the research segment dominated the market in 2024 and it is expected to witness the fastest CAGR from 2025 to 2030
  • Kits & reagent dominated the product segment in 2024, and it is expected to witness the fastest growth in forecast period of 2025-2030
  • Based on specimen, the blood segment dominated the market in 2024. The other body fluids segment is expected to witness the fastest CAGR from 2025 to 2030
  • Based on end-use, the research & academic institutes segment dominated the market in 2024 due to increasing focus on research and development activities for cancer diagnosis and treatment
  • North America dominated the CTC market in 2024, owing to factors such as the presence of key market players Bio-Techne Corporation, Precision Medicine Group LLC, Epic Sciences, APPLIED DNA SCIENCES, INC., and LungLife AI, Inc. and the growth in pharmaceutical & biotechnology research sectors in this region
  • Asia Pacific is expected to register the fastest CAGR over the forecast period due to several companies expanding their presence in countries like Japan

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Application
    • 1.2.3. Product
    • 1.2.4. Specimen
    • 1.2.5. End use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Circulating Tumor Cells Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Advancements in chip technology
      • 3.2.1.2. Expanding applications of CTCs
      • 3.2.1.3. Growing demand for early and rapid cancer diagnosis
      • 3.2.1.4. Growing incidence of cancer
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Consistency-related challenges in CTC detection and enrichment
      • 3.2.2.2. Higher preference for Point-of-Care (POC) testing and nonavailability of POC adaptable CTC tests
      • 3.2.2.3. Lower applicability of CTCs in rare cancers
  • 3.3. Circulating Tumor Cells Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Circulating Tumor Cells Market: Technology Estimates & Trend Analysis

  • 4.1. Technology Segment Dashboard
  • 4.2. Global Circulating Tumor Cells Market Technology Movement Analysis
  • 4.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. CTC Detection & Enrichment Methods
      • 4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.1.2. Immunocapture (Label-based)
        • 4.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
        • 4.4.1.2.2. Positive Selection
          • 4.4.1.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
        • 4.4.1.2.3. Negative Selection
          • 4.4.1.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.1.3. Size-based Separation (Label-free)
        • 4.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
        • 4.4.1.3.2. Membrane-based
          • 4.4.1.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
        • 4.4.1.3.3. Microfluidic-based
          • 4.4.1.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.1.4. Density-based Separation (Label-free)
        • 4.4.1.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.1.5. Combined Methods
        • 4.4.1.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.2. CTC Direct Detection Methods
      • 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.2.2. SERS
        • 4.4.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.2.3. Microscopy
        • 4.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.2.4. Others
        • 4.4.2.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.3. CTC Analysis
      • 4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Circulating Tumor Cells Market: Application Estimates & Trend Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. Global Circulating Tumor Cells Market Application Movement Analysis
  • 5.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Clinical
      • 5.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 5.4.1.2. Risk Assessment
        • 5.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 5.4.1.3. Screening and Monitoring
        • 5.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.2. Research
      • 5.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 5.4.2.2. Cancer Stem Cell & Tumorogenesis Research
        • 5.4.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 5.4.2.3. Drug/Therapy Development
        • 5.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Circulating Tumor Cells Market: Product Estimates & Trend Analysis

  • 6.1. Product Segment Dashboard
  • 6.2. Global Circulating Tumor Cells Market Product Movement Analysis
  • 6.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Kits & reagents
      • 6.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
    • 6.4.2. Blood collection tubes
      • 6.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.3. Devices or systems
      • 6.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Circulating Tumor Cells Market: Specimen Estimates & Trend Analysis

  • 7.1. Specimen Segment Dashboard
  • 7.2. Global Circulating Tumor Cells Market Specimen Movement Analysis
  • 7.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Specimen, 2018 to 2030 (USD Million)
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Blood
      • 7.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
    • 7.4.2. Bone marrow
      • 7.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.3. Other body fluids
      • 7.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Circulating Tumor Cells Market: End Use Estimates & Trend Analysis

  • 8.1. End Use Segment Dashboard
  • 8.2. Global Circulating Tumor Cells Market End Use Movement Analysis
  • 8.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 8.4.1. Research and academic institutes
      • 8.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
    • 8.4.2. Hospital and clinics
      • 8.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.4.3. Diagnostic centers
      • 8.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 9. Circulating Tumor Cells Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Share Analysis, 2024 & 2030
  • 9.2. Regional Market Dashboard
  • 9.3. North America
    • 9.3.1. U.S.
      • 9.3.1.1. Key country dynamics
      • 9.3.1.2. Regulatory framework
      • 9.3.1.3. Competitive scenario
      • 9.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.3.1.5. Target disease prevalence
    • 9.3.2. Canada
      • 9.3.2.1. Key country dynamics
      • 9.3.2.2. Regulatory framework
      • 9.3.2.3. Competitive scenario
      • 9.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.3.2.5. Target disease prevalence
    • 9.3.3. Mexico
      • 9.3.3.1. Key country dynamics
      • 9.3.3.2. Regulatory framework
      • 9.3.3.3. Competitive scenario
      • 9.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.3.3.5. Target disease prevalence
  • 9.4. Europe
    • 9.4.1. UK
      • 9.4.1.1. Key country dynamics
      • 9.4.1.2. Regulatory framework
      • 9.4.1.3. Competitive scenario
      • 9.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.4.1.5. Target disease prevalence
    • 9.4.2. Germany
      • 9.4.2.1. Key country dynamics
      • 9.4.2.2. Regulatory framework
      • 9.4.2.3. Competitive scenario
      • 9.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.4.2.5. Target disease prevalence
    • 9.4.3. France
      • 9.4.3.1. Key country dynamics
      • 9.4.3.2. Regulatory framework
      • 9.4.3.3. Competitive scenario
      • 9.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.4.3.5. Target disease prevalence
    • 9.4.4. Italy
      • 9.4.4.1. Key country dynamics
      • 9.4.4.2. Regulatory framework
      • 9.4.4.3. Competitive scenario
      • 9.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.4.4.5. Target disease prevalence
    • 9.4.5. Spain
      • 9.4.5.1. Key country dynamics
      • 9.4.5.2. Regulatory framework
      • 9.4.5.3. Competitive scenario
      • 9.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.4.5.5. Target disease prevalence
    • 9.4.6. Norway
      • 9.4.6.1. Key country dynamics
      • 9.4.6.2. Regulatory framework
      • 9.4.6.3. Competitive scenario
      • 9.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.4.6.5. Target disease prevalence
    • 9.4.7. Sweden
      • 9.4.7.1. Key country dynamics
      • 9.4.7.2. Regulatory framework
      • 9.4.7.3. Competitive scenario
      • 9.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.4.7.5. Target disease prevalence
    • 9.4.8. Denmark
      • 9.4.8.1. Key country dynamics
      • 9.4.8.2. Regulatory framework
      • 9.4.8.3. Competitive scenario
      • 9.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.4.8.5. Target disease prevalence
  • 9.5. Asia Pacific
    • 9.5.1. Japan
      • 9.5.1.1. Key country dynamics
      • 9.5.1.2. Regulatory framework
      • 9.5.1.3. Competitive scenario
      • 9.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.5.1.5. Target disease prevalence
    • 9.5.2. China
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Regulatory framework
      • 9.5.2.3. Competitive scenario
      • 9.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.5.2.5. Target disease prevalence
    • 9.5.3. India
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. Regulatory framework
      • 9.5.3.3. Competitive scenario
      • 9.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.5.3.5. Target disease prevalence
    • 9.5.4. Australia
      • 9.5.4.1. Key country dynamics
      • 9.5.4.2. Regulatory framework
      • 9.5.4.3. Competitive scenario
      • 9.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.5.4.5. Target disease prevalence
    • 9.5.5. South Korea
      • 9.5.5.1. Key country dynamics
      • 9.5.5.2. Regulatory framework
      • 9.5.5.3. Competitive scenario
      • 9.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.5.5.5. Target disease prevalence
    • 9.5.6. Thailand
      • 9.5.6.1. Key country dynamics
      • 9.5.6.2. Regulatory framework
      • 9.5.6.3. Competitive scenario
      • 9.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.5.6.5. Target disease prevalence
  • 9.6. Latin America
    • 9.6.1. Brazil
      • 9.6.1.1. Key country dynamics
      • 9.6.1.2. Regulatory framework
      • 9.6.1.3. Competitive scenario
      • 9.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.6.1.5. Target disease prevalence
    • 9.6.2. Argentina
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Regulatory framework
      • 9.6.2.3. Competitive scenario
      • 9.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.6.2.5. Target disease prevalence
  • 9.7. MEA
    • 9.7.1. South Africa
      • 9.7.1.1. Key country dynamics
      • 9.7.1.2. Regulatory framework
      • 9.7.1.3. Competitive scenario
      • 9.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.7.1.5. Target disease prevalence
    • 9.7.2. Saudi Arabia
      • 9.7.2.1. Key country dynamics
      • 9.7.2.2. Regulatory framework
      • 9.7.2.3. Competitive scenario
      • 9.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.7.2.5. Target disease prevalence
    • 9.7.3. UAE
      • 9.7.3.1. Key country dynamics
      • 9.7.3.2. Regulatory framework
      • 9.7.3.3. Competitive scenario
      • 9.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.7.3.5. Target disease prevalence
    • 9.7.4. Kuwait
      • 9.7.4.1. Key country dynamics
      • 9.7.4.2. Regulatory framework
      • 9.7.4.3. Competitive scenario
      • 9.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
      • 9.7.4.5. Target disease prevalence

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2. Company/Competition Categorization
  • 10.3. Vendor Landscape
    • 10.3.1. List of key distributors and channel partners
    • 10.3.2. Key customers
    • 10.3.3. Key company position analysis, 2024
    • 10.3.4. QIAGEN
      • 10.3.4.1. Company overview
      • 10.3.4.2. Financial performance
      • 10.3.4.3. Product benchmarking
      • 10.3.4.4. Strategic initiatives
    • 10.3.5. Bio-Techne Corp.
      • 10.3.5.1. Company overview
      • 10.3.5.2. Financial performance
      • 10.3.5.3. Product benchmarking
      • 10.3.5.4. Strategic initiatives
    • 10.3.6. Precision Medicine Group, LLC.
      • 10.3.6.1. Company overview
      • 10.3.6.2. Financial performance
      • 10.3.6.3. Product benchmarking
      • 10.3.6.4. Strategic initiatives
    • 10.3.7. Bio-Rad Laboratories, Inc.
      • 10.3.7.1. Company overview
      • 10.3.7.2. Financial performance
      • 10.3.7.3. Product benchmarking
      • 10.3.7.4. Strategic initiatives
    • 10.3.8. Natera, Inc.
      • 10.3.8.1. Company overview
      • 10.3.8.2. Financial performance
      • 10.3.8.3. Product benchmarking
      • 10.3.8.4. Strategic initiatives
    • 10.3.9. Illumina, Inc.
      • 10.3.9.1. Company overview
      • 10.3.9.2. Financial performance
      • 10.3.9.3. Product benchmarking
      • 10.3.9.4. Strategic initiatives
    • 10.3.10. Cell Microsystems
      • 10.3.10.1. Company overview
      • 10.3.10.2. Financial performance
      • 10.3.10.3. Product benchmarking
      • 10.3.10.4. Strategic initiatives
    • 10.3.11. Greiner Bio One International GmbH
      • 10.3.11.1. Company overview
      • 10.3.11.2. Financial performance
      • 10.3.11.3. Product benchmarking
      • 10.3.11.4. Strategic initiatives
    • 10.3.12. Ikonisys Inc.
      • 10.3.12.1. Company overview
      • 10.3.12.2. Financial performance
      • 10.3.12.3. Product benchmarking
      • 10.3.12.4. Strategic initiatives
    • 10.3.13. Miltenyi Biotec
      • 10.3.13.1. Company overview
      • 10.3.13.2. Financial performance
      • 10.3.13.3. Product benchmarking
      • 10.3.13.4. Strategic initiatives
    • 10.3.14. Creative Bioarray
      • 10.3.14.1. Company overview
      • 10.3.14.2. Financial performance
      • 10.3.14.3. Product benchmarking
      • 10.3.14.4. Strategic initiatives
    • 10.3.15. BioFluidica
      • 10.3.15.1. Company overview
      • 10.3.15.2. Financial performance
      • 10.3.15.3. Product benchmarking
      • 10.3.15.4. Strategic initiatives
    • 10.3.16. Abnova Corporation
      • 10.3.16.1. Company overview
      • 10.3.16.2. Financial performance
      • 10.3.16.3. Product benchmarking
      • 10.3.16.4. Strategic initiatives
    • 10.3.17. Biolidics Limited
      • 10.3.17.1. Company overview
      • 10.3.17.2. Financial performance
      • 10.3.17.3. Product benchmarking
      • 10.3.17.4. Strategic initiatives
    • 10.3.18. Creativ MicroTech, Inc.
      • 10.3.18.1. Company overview
      • 10.3.18.2. Financial performance
      • 10.3.18.3. Product benchmarking
      • 10.3.18.4. Strategic initiatives
    • 10.3.19. LungLife AI
      • 10.3.19.1. Company overview
      • 10.3.19.2. Financial performance
      • 10.3.19.3. Product benchmarking
      • 10.3.19.4. Strategic initiatives
    • 10.3.20. Epic Sciences
      • 10.3.20.1. Company overview
      • 10.3.20.2. Financial performance
      • 10.3.20.3. Product benchmarking
      • 10.3.20.4. Strategic initiatives
    • 10.3.21. Rarecells Diagnostics
      • 10.3.21.1. Company overview
      • 10.3.21.2. Financial performance
      • 10.3.21.3. Product benchmarking
      • 10.3.21.4. Strategic initiatives
    • 10.3.22. ScreenCell
      • 10.3.22.1. Company overview
      • 10.3.22.2. Financial performance
      • 10.3.22.3. Product benchmarking
      • 10.3.22.4. Strategic initiatives
    • 10.3.23. Menarini Silicon Biosystems
      • 10.3.23.1. Company overview
      • 10.3.23.2. Financial performance
      • 10.3.23.3. Product benchmarking
      • 10.3.23.4. Strategic initiatives
    • 10.3.24. APPLIED DNA SCIENCES, INC.
      • 10.3.24.1. Company overview
      • 10.3.24.2. Financial performance
      • 10.3.24.3. Product benchmarking
      • 10.3.24.4. Strategic initiatives
    • 10.3.25. Sysmex Corporation
      • 10.3.25.1. Company overview
      • 10.3.25.2. Financial performance
      • 10.3.25.3. Product benchmarking
      • 10.3.25.4. Strategic initiatives
    • 10.3.26. STEMCELL Technologies, Inc.
      • 10.3.26.1. Company overview
      • 10.3.26.2. Financial performance
      • 10.3.26.3. Product benchmarking
      • 10.3.26.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America circulating tumor cells market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 4 North America circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 5 North America circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 6 North America circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 7 North America circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 8 U.S. circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 9 U.S. circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 10 U.S. circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 11 U.S. circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 12 U.S. circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 13 Canada circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 14 Canada circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 15 Canada circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 16 Canada circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 17 Canada circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Mexico circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 19 Mexico circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 20 Mexico circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 21 Mexico circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 22 Mexico circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 23 Europe circulating tumor cells market, by region, 2018 - 2030 (USD Million)
  • Table 24 Europe circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 25 Europe circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 26 Europe circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 27 Europe circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 28 Europe circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 29 UK circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 30 UK circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 31 UK circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 32 UK circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 33 UK circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Germany circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 35 Germany circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 36 Germany circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 37 Germany circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 38 Germany circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 39 Italy circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 40 Italy circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 41 Italy circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 42 Italy circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 43 Italy circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 44 France circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 45 France circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 46 France circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 47 France circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 48 France circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 49 Spain circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 50 Spain circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 51 Spain circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 52 Spain circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 53 Spain circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Sweden circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 55 Sweden circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 56 Sweden circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 57 Sweden circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 58 Sweden circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Denmark circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 60 Denmark circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 61 Denmark circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 62 Denmark circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 63 Denmark circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 64 Norway circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 65 Norway circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 66 Norway circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 67 Norway circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 68 Norway circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Asia Pacific circulating tumor cells market, by region, 2018 - 2030 (USD Million)
  • Table 70 Asia Pacific circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 71 Asia Pacific circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 72 Asia Pacific circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 73 Asia Pacific circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 74 Asia Pacific circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 75 China circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 76 China circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 77 China circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 78 China circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 79 China circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 80 Japan circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 81 Japan circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 82 Japan circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 83 Japan circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 84 Japan circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 85 India circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 86 India circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 87 India circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 88 India circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 89 India circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 90 South Korea circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 91 South Korea circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 92 South Korea circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 93 South Korea circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 94 South Korea circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 95 Australia circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 96 Australia circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 97 Australia circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 98 Australia circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 99 Australia circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 100 Thailand circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 101 Thailand circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 102 Thailand circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 103 Thailand circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 104 Thailand circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 105 Latin America circulating tumor cells market, by region, 2018 - 2030 (USD Million)
  • Table 106 Latin America circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 107 Latin America circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 108 Latin America circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 109 Latin America circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 110 Latin America circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 111 Brazil circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 112 Brazil circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 113 Brazill circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 114 Brazil circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 115 Brazil circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 116 Argentina circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 117 Argentina circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 118 Argentina circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 119 Argentina circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 120 Argentina circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 121 Middle East Africa circulating tumor cells market, by region, 2018 - 2030 (USD Million)
  • Table 122 Middle East Africa circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 123 Middle East Africa circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 124 Middle East Africa circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 125 Middle East Africa circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 126 Middle East Africa circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 127 South Africa circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 128 South Africa circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 129 South Africa circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 130 South Africa circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 131 South Africa circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 132 Saudi Arabia circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 133 Saudi Arabia circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 134 Saudi Arabia circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 135 Saudi Arabia circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 136 Saudi Arabia circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 137 UAE circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 138 UAE circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 139 UAE circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 140 UAE circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 141 UAE circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
  • Table 142 Kuwait circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 143 Kuwait circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 144 Kuwait circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 145 Kuwait circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 146 Kuwait circulating tumor cells market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Circulating tumor cells market: market outlook
  • Fig. 9 Circulating tumor cells competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Circulating tumor cells market driver impact
  • Fig. 15 Circulating tumor cells market restraint impact
  • Fig. 16 Circulating tumor cells market strategic initiatives analysis
  • Fig. 17 Circulating tumor cells market: Technology movement analysis
  • Fig. 18 Circulating tumor cells market: Technology outlook and key takeaways
  • Fig. 19 CTC detection & enrichment methods market estimates and forecast, 2018 - 2030
  • Fig. 20 Immunocapture (label-based) estimates and forecast, 2018 - 2030
  • Fig. 21 Positive selection market estimates and forecast, 2018 - 2030
  • Fig. 22 Negative selection estimates and forecast, 2018 - 2030
  • Fig. 23 Size-based separation (label-free) market estimates and forecast, 2018 - 2030
  • Fig. 24 Membrane-based estimates and forecast, 2018 - 2030
  • Fig. 25 Microfluidic-based estimates and forecast, 2018 - 2030
  • Fig. 26 Density-based Separation (Label-free) estimates and forecast, 2018 - 2030
  • Fig. 27 Combined Methods estimates and forecast, 2018 - 2030
  • Fig. 28 CTC direct detection methods estimates and forecast, 2018 - 2030
  • Fig. 29 SERS estimates and forecast, 2018 - 2030
  • Fig. 30 Microscopy estimates and forecast, 2018 - 2030
  • Fig. 31 Others estimates and forecast, 2018 - 2030
  • Fig. 32 CTC Analysis estimates and forecast, 2018 - 2030
  • Fig. 33 Circulating tumor cells Market: Application movement Analysis
  • Fig. 34 Circulating tumor cells market: Application outlook and key takeaways
  • Fig. 35 Clinical/ Liquid Biopsy market estimates and forecasts, 2018 - 2030
  • Fig. 36 Risk Assessment market estimates and forecasts, 2018 - 2030
  • Fig. 37 Screening and Monitoring market estimates and forecasts, 2018 - 2030
  • Fig. 38 Research market estimates and forecasts, 2018 - 2030
  • Fig. 39 Cancer Stem Cell & Tumorogenesis Research market estimates and forecasts, 2018 - 2030
  • Fig. 40 Drug/Therapy Development market estimates and forecasts, 2018 - 2030
  • Fig. 41 Circulating tumor cells Market: Product movement Analysis
  • Fig. 42 Circulating tumor cells market: Product outlook and key takeaways
  • Fig. 43 Kits & reagents market estimates and forecasts, 2018 - 2030
  • Fig. 44 Blood collection tubes market estimates and forecasts, 2018 - 2030
  • Fig. 45 Devices or Systems market estimates and forecasts, 2018 - 2030
  • Fig. 46 Circulating tumor cells Market: Specimen movement Analysis
  • Fig. 47 Circulating tumor cells market: Specimen outlook and key takeaways
  • Fig. 48 Blood market estimates and forecasts, 2018 - 2030
  • Fig. 49 Bone marrow market estimates and forecasts, 2018 - 2030
  • Fig. 50 Other body fluids market estimates and forecasts, 2018 - 2030
  • Fig. 51 Circulating tumor cells Market: End use movement Analysis
  • Fig. 52 Circulating tumor cells market: End use outlook and key takeaways
  • Fig. 53 Research and academic institutes market estimates and forecasts, 2018 - 2030
  • Fig. 54 Hospital and clinics market estimates and forecasts, 2018 - 2030
  • Fig. 55 Diagnostic centers market estimates and forecasts, 2018 - 2030
  • Fig. 56 Global circulating tumor cells market: Regional movement analysis
  • Fig. 57 Global circulating tumor cells market: Regional outlook and key takeaways
  • Fig. 58 North America, by country
  • Fig. 59 North America
  • Fig. 60 North America market estimates and forecasts, 2018 - 2030
  • Fig. 61 U.S. country dynamics
  • Fig. 62 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 63 Canada country dynamics
  • Fig. 64 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 65 Mexico country dynamics
  • Fig. 66 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 67 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 68 UK country dynamics
  • Fig. 69 UK market estimates and forecasts, 2018 - 2030
  • Fig. 70 Germany country dynamics
  • Fig. 71 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 72 France country dynamics
  • Fig. 73 France market estimates and forecasts, 2018 - 2030
  • Fig. 74 Italy country dynamics
  • Fig. 75 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 76 Spain country dynamics
  • Fig. 77 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 78 Denmark country dynamics
  • Fig. 79 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 80 Sweden country dynamics
  • Fig. 81 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 82 Norway country dynamics
  • Fig. 83 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 84 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 85 China country dynamics
  • Fig. 86 China market estimates and forecasts, 2018 - 2030
  • Fig. 87 Japan country dynamics
  • Fig. 88 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 89 India country dynamics
  • Fig. 90 India market estimates and forecasts, 2018 - 2030
  • Fig. 91 Thailand country dynamics
  • Fig. 92 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 93 South Korea country dynamics
  • Fig. 94 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 95 Australia country dynamics
  • Fig. 96 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 97 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 98 Brazil country dynamics
  • Fig. 99 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 100 Argentina country dynamics
  • Fig. 101 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 102 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 103 South Africa country dynamics
  • Fig. 104 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 105 Saudi Arabia country dynamics
  • Fig. 106 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 107 UAE country dynamics
  • Fig. 108 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 109 Kuwait country dynamics
  • Fig. 110 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 111 Market position of key market players- Circulating tumor cells market